NCT00617565View on ClinicalTrials.gov

Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

219

Participants

Timeline

Start Date

July 8, 2003

Primary Completion Date

November 26, 2003

Study Completion Date

November 26, 2003

Conditions
DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
Interventions
DRUG

biphasic insulin aspart

DRUG

biphasic human insulin

Trial Locations (6)

100029

Novo Nordisk Investigational Site, Beijing

100034

Novo Nordisk Investigational Site, Beijing

100730

Novo Nordisk Investigational Site, Beijing

100853

Novo Nordisk Investigational Site, Beijing

200032

Novo Nordisk Investigational Site, Shanghai

200433

Novo Nordisk Investigational Site, Shanghai

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY